Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. (Q38386037)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 March 2015

Language	Label	Description	Also known as
English	Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.	scientific article published on 18 March 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

author name string

Akira Kawai

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Nobuhito Araki

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hideshi Sugiura

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Takafumi Ueda

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tsukasa Yonemoto

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mitsuru Takahashi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hideo Morioka

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hiroaki Hiraga

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Toru Hiruma

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Toshiyuki Kunisada

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Akihiko Matsumine

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Tadashi Hasegawa

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

18 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

406-416

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795406%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Soft-tissue sarcomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Translocation-related sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of trabectedin (ET-743): a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of genetic testing in soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Proposal for the use of progression-free survival in unblinded randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety evaluation of trabectedin in treatment of soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970098-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38386037&oldid=1756240955"